LifeMD, Inc. (NASDAQ: LFMD) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $62.2 million versus the consensus estimate of $66.29 million.

GUIDANCE:

LifeMD, Inc. sees Q3 2025 revenue of $61-63 million, versus the consensus of $67.7 million.

For the third quarter of 2025, the Company expects:

• Total revenue in the range of $61 million to $63 million, with telehealth revenue in the range of $48 million to $50 million.
• Adjusted EBITDA in the range of $6 million to $7 million, with telehealth adjusted EBITDA in the range of $3 million to $4 million.

LifeMD, Inc. sees FY2025 revenue of $250-255 million, versus the consensus of $270.4 million.

For the full year 2025, the Company expects:

• Total revenue in the range of $250 million to $255 million, compared with previous guidance of $268 million to $275 million.
• Telehealth revenue in the range of $195 million to $200 million, compared with $208 million to $213 million previously.
• Adjusted EBITDA in the range of $27 million to $29 million, compared with $31 million to $33 million previously.
• Telehealth adjusted EBITDA is now forecast to be in the range of $14 million to $16 million, down from $21 million previously.

For earnings history and earnings-related data on LifeMD, Inc. (LFMD) click here.